

Inpatient stays: High cost drug list

Update to the “Requirements for Complete Claims and Encounter Data Submission”

Effective July 1, 2026, UnitedHealthcare hereby requires inclusion of the Healthcare Common Procedure Coding System (HCPCS) and the National Drug Code (NDC) codes on all UnitedHealthcare commercial plan claims with an inpatient place of service when one of the following specialty drugs is administered inpatient:

Drug name	Description	HCPCS
Elevidys®	Injection, delandistrogene moxeparvovec-rokl	J1413
Gamifant®	Injection, emapalumab-lzsg	J9210
Hemgenix®	Injection, etranacogene dezaparvovec-drlb	J1411
Itvisma®	Injection, onasemnogene abeparvovec-brve	J3405
Luxturna®	Injection, voretigene neparvovec-rzyl	J3398
Spinraza®	Injection, nusinersen	J2326
Vyjuvek®	Injection, beremagene geperpavec-svdt for topical administration	J3401
Zolgensma®	Injection, onasemnogene abeparvovec-xioi	J3399

This is an update to the **Unique billing scenarios and requirements** section found on page 138 in the existing **Requirements for complete claims and encounter data submission** protocol found on page 137 in the UnitedHealthcare Provider Administrative Guide.



Questions? We're here to help.

For chat options and contact information, visit UHCprovider.com/contactus.